{
  "id": "asdas_crp",
  "title": "Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP)",
  "description": "Stratifies severity of ankylosing spondylitis (AS) using clinical and laboratory data, specifically CRP. ASAS-endorsed disease activity score for monitoring AS treatment response.",
  "category": "rheumatology",
  "version": "2009",
  "parameters": [
    {
      "name": "back_pain",
      "type": "float",
      "required": true,
      "description": "Overall level of AS neck, back, or hip pain (0-10 scale)",
      "validation": {
        "min": 0,
        "max": 10
      },
      "unit": "scale"
    },
    {
      "name": "morning_stiffness",
      "type": "float",
      "required": true,
      "description": "Overall level of morning stiffness from the time you wake up (0-10 scale)",
      "validation": {
        "min": 0,
        "max": 10
      },
      "unit": "scale"
    },
    {
      "name": "patient_global",
      "type": "float",
      "required": true,
      "description": "Patient global assessment: How active was your spondylitis on average during the last week (0-10 scale)",
      "validation": {
        "min": 0,
        "max": 10
      },
      "unit": "scale"
    },
    {
      "name": "peripheral_pain",
      "type": "float",
      "required": true,
      "description": "Overall level of pain/swelling in joints other than neck, back, or hips (0-10 scale)",
      "validation": {
        "min": 0,
        "max": 10
      },
      "unit": "scale"
    },
    {
      "name": "crp",
      "type": "float",
      "required": true,
      "description": "C-reactive protein (CRP) level",
      "validation": {
        "min": 0,
        "max": 300
      },
      "unit": "mg/L"
    }
  ],
  "result": {
    "name": "asdas_crp_score",
    "type": "float",
    "unit": "score",
    "description": "ASDAS-CRP disease activity score"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 0,
        "max": 1.3,
        "stage": "Inactive Disease",
        "description": "Inactive ankylosing spondylitis",
        "interpretation": "Disease activity is in remission. Continue current therapy and monitor regularly. Consider tapering biological therapy if sustained remission achieved. Maintain physical therapy and exercise program."
      },
      {
        "min": 1.3,
        "max": 2.1,
        "stage": "Moderate Disease Activity",
        "description": "Moderate ankylosing spondylitis activity",
        "interpretation": "Moderate disease activity present. Optimize current treatment regimen. Consider escalation to biological therapy if not already on biologics. Increase physical therapy intensity and ensure adherence to treatment plan."
      },
      {
        "min": 2.1,
        "max": 3.5,
        "stage": "High Disease Activity", 
        "description": "High ankylosing spondylitis activity",
        "interpretation": "High disease activity requiring treatment intensification. Consider starting or switching biological therapy (TNF inhibitors, IL-17 inhibitors, JAK inhibitors). Evaluate treatment adherence and optimize conventional therapy. Close monitoring required."
      },
      {
        "min": 3.5,
        "max": 10,
        "stage": "Very High Disease Activity",
        "description": "Very high ankylosing spondylitis activity",
        "interpretation": "Very high disease activity indicating urgent need for treatment modification. Immediate consideration for biological therapy initiation or switching. Evaluate for comorbidities and extra-articular manifestations. Consider short-term corticosteroids if appropriate."
      }
    ]
  },
  "references": [
    "Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Jan;68(1):18-24. doi: 10.1136/ard.2008.094870.",
    "van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, Braun J, Landewé R. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Dec;68(12):1811-8. doi: 10.1136/ard.2008.100826.",
    "Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011 Jan;70(1):47-53. doi: 10.1136/ard.2010.138594."
  ],
  "formula": "ASDAS-CRP = 0.12 × Back Pain + 0.06 × Duration of Morning Stiffness + 0.11 × Patient Global + 0.07 × Peripheral Pain/Swelling + 0.58 × Ln(CRP+1). Cut-offs: <1.3 (inactive), 1.3-2.1 (moderate), 2.1-3.5 (high), >3.5 (very high).",
  "notes": [
    "ASDAS-CRP is the preferred version over ASDAS-ESR due to better discriminatory ability and lower variability.",
    "All patient-reported measures (back pain, morning stiffness, patient global, peripheral pain) are assessed on a 0-10 numerical rating scale.",
    "The score is endorsed by the Assessment of SpondyloArthritis international Society (ASAS) and is the recommended outcome measure for clinical trials.",
    "Clinically important improvement is defined as a change ≥1.1 units, and major improvement as a change ≥2.0 units.",
    "The score should be calculated regularly to monitor treatment response and guide therapeutic decisions.",
    "CRP values should be obtained using standardized laboratory methods, with results reported in mg/L.",
    "The natural logarithm of (CRP+1) is used to normalize the distribution and prevent issues with zero values."
  ]
}